Robin’s background as a scientist combined with her extensive experience developing health economic strategy have contributed to her current focus guiding adoption of precision medicine diagnostics into accepted health care practice, helping payers and regulators update processes in order to reflect advancements in science and medicine. As Vice President, Health Care Economics and Reimbursement, she developed and implemented a payer and regulatory strategy that has resulted in widespread acceptance of VeriStrat®, Biodesix’ first commercially available molecular diagnostic test. Prior to joining Biodesix, Robin held a leadership role in payer and government relations at Precision Therapeutics (now Helomics). Robin’s background includes extensive experience with corporate finance, including venture capital, preparing for an IPO, and SPAC financing. She also spent several years as a researcher at the University of Pittsburgh Medical Center. Robin holds a B.S. in molecular biology and an MBA in Finance from the Joseph M. Katz Graduate School of Business, both completed at the University of Pittsburgh.